GLP-1 receptor agonists and fenofibrate medications significantly reduced the risk for developing diabetic macular edema, ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

A new study in the journal of Ophthalmology Retina showed that diabetic macular edema (DME) affected 11.1% of people with ...

September 21, 2012 — The US Food and Drug Administration (FDA) has approved aflibercept injection (Eylea, Regeneron Pharmaceuticals) for treating macular edema following central retinal vein occlusion ...

You may think diabetic macular edema (DME) affects older people only. But the truth is, the eye condition can develop in anyone with type 1 or type 2 diabetes. DME is more common in people with type 2 ...

A biosimilar demonstrated comparable efficacy and safety to aflibercept in treating diabetic macular edema. The vascular endothelial growth factor inhibitor was one of two aflibercept biosimilars ...

When you have type 1 or type 2 diabetes, it can lead to even more health problems. Diabetic macular edema (DME) is an eye disease that happens to about 10% of people with diabetes. It can happen to ...

EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults with type 2 diabetes did not have higher risk for ...

Patients with nonischemic branch retinal vein occlusion had their macular edema severity associated with leakage index. Leakage index was found to have an association with macular edema severity in ...